FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a composition comprising a Factor VIII complex and one or more von Willebrand Factor peptides, where von Willebrand Factor peptides contain at least amino acids 764–1035 and 1691–1905 of SEQ ID NO: 1, but do not contain amino acids 2255–2645 of SEQ ID NO: 1, and can be used in medicine.
EFFECT: said composition is used for effective treatment of haemophilia.
12 cl, 14 dwg, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST XI CLOTTING FACTOR | 2017 |
|
RU2757314C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTIBODIES AGAINST TISSUE FACTOR PATHWAY INHIBITOR AND THEIR USE | 2016 |
|
RU2815681C1 |
| RECOMBINANT MODIFIED FIBROBLAST GROWTH FACTORS AND THEIR THERAPEUTIC USE | 2018 |
|
RU2811435C2 |
| IMPROVED FACTOR IX FUNCTION PROTEIN AND ITS CONJUGATE AND THEIR USE | 2020 |
|
RU2794350C1 |
| PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTING AND/OR TREATING A DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF REDUCING OR LOSING ACTIVITY OF THE BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED COAGULATION FACTOR VIII | 2015 |
|
RU2721910C2 |
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| POLYPEPTIDES THAT ARE SOLUBLE RECEPTORS OF FIBROBLAST GROWTH FACTOR 3 (sFGFR3), AND WAYS OF THEIR APPLICATION | 2017 |
|
RU2751483C2 |
| GENE THERAPY OF HYPOPHOSPHATEMIC DISEASES ASSOCIATED WITH FIBROBLAST GROWTH FACTOR 23 | 2020 |
|
RU2815545C2 |
| GLYCOSYLATED FUSED PROTEINS VWF WITH IMPROVED PHARMACOKINETICS | 2017 |
|
RU2782212C2 |
